(Nasdaq: MDCX) And The Rare Disease Program That Could Redefine Skin Cancer Care

On July 27, 2026, Medicus Pharma Ltd. (NASDAQ: MDCX)

Any content you receive is for information purposes only. Always conduct your own research. *Disseminated on Behalf of Medicus Pharma Ltd. (Nasdaq: MDCX) And The Rare Disease Program That Could Redefine Skin Cancer Care July 31st Greetings Readers, On July 27th, 2026, Medicus Pharma Ltd. (NASDAQ: MDCX) received FDA authorization that market watchers should not overlook. The agency issued a "Study May Proceed" letter for SKNJCT-005, clearing the company to initiate an NDA-enabling Phase 2b registrational clinical trial of SkinJect® in patients with Gorlin Syndrome. That clearance signals a meaningful shift from exploratory Phase 2 evidence into registrational territory. Gorlin Syndrome, or Nevoid Basal Cell Carcinoma Syndrome, is a rare genetic disorder that puts patients through a relentless cycle of surgical procedures. Affected individuals can develop dozens to over 1,000 basal cell carcinoma lesions in a lifetime, often beginning in childhood or adolescence. There is currently no FDA-approved lesion-directed treatment for this population. SkinJect is engineered to address that gap. SkinJect is a dissolvable microneedle array patch that delivers doxorubicin chemotherapy directly into basal cell carcinoma tumors. Prior Phase 2 data from SKNJCT-003, which enrolled 90 patients across nine U.S. sites, showed 64% clinical clearance and 55% histological clearance at Day 57 in the 200 mcg dose group, with no treatment-related serious adverse events. The data demonstrated a clear dose-response relationship, forming what the company has characterized as "decision-grade" evidence. The registrational study SKNJCT-005 will enroll up to 50 Gorlin Syndrome patients, treating two to four target lesions simultaneously. The FDA required extended patient follow-up of at least two years, a protocol enhancement that management views as reinforcing durability evaluation for the therapy rather than a constraint. Executive Chairman and Medicus Pharma CEO, Dr. Raza Bokhari, described the clearance as "a significant regulatory milestone." Running in parallel, MDCX is advancing Teverelix, a long-acting injectable GnRH antagonist targeting advanced prostate cancer in patients with elevated cardiovascular risk. The FDA granted "Study May Proceed" clearance for a Teverelix Phase 2b dose-optimization study in February 2026, and the company has filed a substantial modification application through the EU Clinical Trials Information System for a European expansion. Together, the two clinical programs are targeting what MDCX estimates to be approximately $8Bn in addressable markets across multiple indications. Medicus Pharma Ltd. is a precision-guided biotech company operating across three continents. The company's core strategy is a "de-risk and partner" model: advance novel therapeutic assets through Phase 2 proof-of-concept clinical trials, then pursue licensing or commercialization partnerships with established pharmaceutical companies. Its lead asset, SkinJect (D-MNA), is developed under the FDA's 505(b)(2) regulatory pathway, leveraging existing safety data on doxorubicin to potentially compress the review timeline. The company acquired Teverelix through its August 2025 purchase of UK-based Antev Ltd., adding a second late-stage program targeting men with advanced prostate cancer and high cardiovascular risk. Phase 1 Teverelix data at AACE 2026 showed predictable, dose-dependent hormone suppression with no unexpected safety signals. Strategic partnerships include collaboration with Reliant AI Inc. on clinical analytics and a memorandum of understanding with Helix Nanotechnologies for mRNA vaccine applications. 6 Potential Catalysts Pin (Nasdaq: MDCX) To Friday's Watchlist #1. FDA Registrational Clearance Opens Path to Potential NDA. The July 27th, 2026 authorization for SKNJCT-005 positions MDCX as the first company advancing a lesion-directed therapy toward potential NDA submission specifically for Gorlin Syndrome, a condition with no currently approved lesion-directed treatment option. #2. Orphan Drug Designation Could Unlock Seven-Year Exclusivity. The April 2026 application for Orphan Drug Designation for SkinJect in Gorlin Syndrome, if granted, would deliver MDCX a potential $5Mn-plus NDA fee exemption and seven years of market exclusivity upon FDA approval. #3. Rare Pediatric Disease Filing Could Yield Priority Review Voucher. MDCX filed for Rare Pediatric Disease Designation with the FDA in June 2026, a status that, if granted, could make the company eligible for a Priority Review Voucher upon NDA approval, a regulatory asset with demonstrated value in pharmaceutical licensing transactions. #4. Teverelix Advancing on Two Regulatory Fronts Simultaneously. With FDA Phase 2b clearance secured in February 2026 and an EU regulatory submission filed through the CTIS platform, MDCX is advancing Teverelix across two major pharmaceutical markets simultaneously, targeting a combined addressable market the company estimates at approximately $6Bn. #5. 505(b)(2) Pathway Compresses the Traditional Approval Timeline. The FDA's confirmation of the 505(b)(2) pathway for SkinJect means MDCX can incorporate existing safety data on doxorubicin into its regulatory submission, a strategic advantage that may reduce both cost and timeline relative to a new chemical entity. #6. Three-Continent Clinical Footprint Strengthens Regulatory Portfolio. MDCX has secured full regulatory approvals from the UK's MHRA, HRA, and WREC, dosed the first patient in a UAE study through Cleveland Clinic Abu Dhabi, and is actively enrolling in U.S. sites, giving the registrational dataset a global breadth that could strengthen any future partnering discussions. Final Take Medicus Pharma Ltd. (Nasdaq: MDCX) is not making noise for its own sake. Every announcement from this company over the past 18 months has carried regulatory or clinical weight: Phase 2 data, FDA clearances, Orphan Drug applications, conference presentations, and now a registrational trial authorization for a rare disease with no existing approved therapy. That is a meaningful pattern. If you are watching the biotech space for names with multiple near-term regulatory milestones and a pipeline designed around clinical validation first, MDCX is one worth keeping on your radar as 2026 unfolds. We're initiating coverage on Medicus Pharma Ltd. (Nasdaq: MDCX). Be on the lookout as updates will be coming out soon. Keep your eyes peeled. Sincerely, Kai Parker StockWireNews More Sources: MDCX Website (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice